NEW YORK (GenomeWeb) – LifeCodexx and Charité–University Medicine Berlin announced today that they have partnered to develop an assay for the early detection of preeclampsia.

The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology, which exploits the different methylation profiles of maternal and fetal DNA found in maternal plasma. The company recently received CE marking for a version of its PrenaTest fetal trisomy 21 assay based on the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.